Ottawa Hospital Research Institute

Health Canada Approves UPLIZNA® (inebilizumab for injection) for the Treatment of Neuromyelitis Optica Spectrum Disorders (NMOSD)

Retrieved on: 
Tuesday, January 16, 2024
Death, Fellow, Patient, Therapy, Ottawa Hospital Research Institute, Multiple sclerosis, Paratriathlon, University, ANVISA, Autoimmune disease, Risk, Food, Disease, Central nervous system, Labour, Ministry of Health, FDA, Pain, Physician, Inflammation, NMOSD, Clinical trial, B cell, Health Canada, Paralysis, Brazilian Health Regulatory Agency, Pharmaceutical industry

-- NMOSD is a devastating autoimmune disease of severe and recurrent central nervous system attacks which can result in blindness, paralysis and death –

Key Points: 
  • "Just a single NMOSD attack can have a life-altering impact, including pain, debilitation and irreversible vision loss.
  • Health Canada based its approval of UPLIZNA on results from the N-MOmentum pivotal trial ( 2014-000253-36 ), the largest NMOSD clinical trial to date.
  • UPLIZNA demonstrated a significant reduction in the risk of an NMOSD attack with only two infusions per year, following the initial loading doses.
  • "We can now accurately diagnose NMOSD, which is distinctly different from MS and warrants specific treatment.

Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Early-Stage Breast Cancer in a Podium Poster Spotlight Discussion at the 2023 SABCS

Retrieved on: 
Friday, December 8, 2023
Woman, Safety, Therapy, Ottawa Hospital Research Institute, Intensity, Podium, Breast cancer, Fatigue, Patient, Gene expression profiling, Necrosis, The Ottawa Hospital, T helper cell, Immunotherapy, Breast, CD4, Gene expression, Biomarker, Mastectomy, MD, Nausea, Diagnosis, Cancer, University, Downregulation and upregulation, Neoplasm, News, Publication, Injection, NK, Vaccine, Medical imaging

"A large unmet need in the treatment of breast cancer is that the majority of breast cancers are immune quiescent; resulting in minimal response to immunotherapies.

Key Points: 
  • "A large unmet need in the treatment of breast cancer is that the majority of breast cancers are immune quiescent; resulting in minimal response to immunotherapies.
  • A functional pathway enrichment analysis was conducted and confirmed positive changes in T-cell activation, lymphocyte activation and inflammatory response.
  • Over 95% of treatment-emergent adverse events (TEAEs) were low grade 1 or 2 primarily localized pain, fatigue, and nausea.
  • We see the potential opportunity for our technology and drug products in both the metastatic and presurgical settings for many types of cancers."

The Health Management Academy Solves for Nurse Manager Overload to Measure Span-of-Control Across 20 Domains

Retrieved on: 
Tuesday, November 21, 2023
Nursing, National Vanguard (American organization), Organization, Span, Overload, Workforce, FAAN, Investment, RN, University Hospitals Association, The Ottawa Hospital, Data collection, Ottawa Hospital Research Institute, Partnership, Catalysis, Workload, American Hospital Association

The Health Management Academy created the Span-of-Control Tool for Frontline Clinical Leaders to help nurse executives assess the total scope of responsibility for leaders overseeing inpatient areas of service.

Key Points: 
  • The Health Management Academy created the Span-of-Control Tool for Frontline Clinical Leaders to help nurse executives assess the total scope of responsibility for leaders overseeing inpatient areas of service.
  • The tool, adapted from The Ottawa Hospital's 2005 validated tool, measures the relative impact of 20 variables that affect manager workload and evaluates whether manager span-of-control is appropriate.
  • Since 1998, The Health Management Academy has cultivated the premier community of healthcare's most influential changemakers from the top U.S. health systems and innovative industry partners.
  • To learn more, visit hmacademy.com and follow The Health Management Academy on LinkedIn .

Cytonus expands its Scientific Advisory Board with Oncolytic Virus expert John C. Bell, PhD

Retrieved on: 
Thursday, November 16, 2023
Royal Society, ISCB Senior Scientist Award, Research, Therapy, Potyvirus, Ottawa Hospital Research Institute, Immunology, McGill University, Vaccine, Royal, Bell, Science, University, Cancer, Virus, Outline of health sciences, McMaster University, Doctor of Philosophy, Microbiology, Medical Research Council, University of Ottawa, Pharmaceutical industry, Management, Medicine, Biochemistry, MD

SAN DIEGO, Nov. 16, 2023 /PRNewswire-PRWeb/ -- Cytonus Therapeutics, Inc., announced today that the company has expanded its Scientific Board of Advisors with the appointment of University of Ottawa Professor and pioneering researcher in the field of oncolytic viruses John C. Bell, PhD.

Key Points: 
  • Board Expansion for Cytonus Therapeutics, Inc.
    SAN DIEGO, Nov. 16, 2023 /PRNewswire-PRWeb/ -- Cytonus Therapeutics, Inc., announced today that the company has expanded its Scientific Board of Advisors with the appointment of University of Ottawa Professor and pioneering researcher in the field of oncolytic viruses John C. Bell, PhD.
  • "It is a great privilege for Cytonus to be joined by Professor Bell, who is an international leader in the field of modern viral immunotherapeutics."
  • commented Cytonus' cofounder and Chief Scientific Innovator, Richard Klemke, PhD.
  • Cytonus' Scientific Advisory Board is comprised of accomplished business leaders, distinguished research scientists, and key opinion leaders from prestigious academic institutions, immune-oncology centers, cell therapy centers, and private industry.

Canadian Nurses Foundation Announces Annual Fundraiser to Provide New Mental Health Supports and Grow Nursing Scholarship Program

Retrieved on: 
Wednesday, October 11, 2023
Shift, Night Shift, CNF, Mental Health Commission of Canada, Nursing, Canadian Nurses Association, L'Oréal, Lighting, American Nurses Foundation, Mental health, Ottawa Hospital Research Institute, The Ottawa Hospital, Véronique, University of Ottawa Heart Institute, Night

OTTAWA, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Canadian Nurses Foundation (CNF), a leading national charity that invests in nurses, nursing students and nursing education, will host its annual fundraiser, The Night Shift: Lighting Up the Night for Nurses on November 2, 2023 at Ottawa’s National Arts Centre. Funds raised will go towards the charity’s growing mental health programs, as well as its scholarship program which offers over 100 scholarships and bursaries to nursing students across the country each year.

Key Points: 
  • Funds raised will go towards the charity’s growing mental health programs, as well as its scholarship program which offers over 100 scholarships and bursaries to nursing students across the country each year.
  • “Canadian nurses have faced immense trials and challenges over the past few years that have negatively affected their psychological well-being, which also impacts the health outcomes of Canadians and our entire health care system,” said Rob Gottschalk, CEO, Canadian Nurses Foundation.
  • Most recently, CNF has partnered with the Mental Health Commission of Canada to fund programming and training to help build a well-resourced nursing community with a focus on mental health.
  • To purchase tickets for this can’t-miss event, visit cnfnightshift.ca and follow us on Facebook @cnf.fiic, Instagram @canadiannursesfoundation and X (Twitter) @theCNF using #CNFnightshift

Lumenix and The Ottawa Hospital Partner to Implement the Artificially Intelligent Monitoring System to Enhance Patient Care, Support Clinical Staff and Hospital Operations

Retrieved on: 
Tuesday, September 26, 2023
Civic, Partnership, Hand, OHRI, The Ottawa Hospital, Intelligence, Learning, Research, AIMS, Hospital, Patient safety, Nursing, Ottawa Hospital Research Institute, Artificial intelligence, Robotics, Health, Medical device

Lumenix, a leader in building technologies and artificial intelligence, is set to install its world-leading and clinically-validated Artificially Intelligent Monitoring System (AIMS) platform technology at the Ottawa Hospital Civic Campus in the fall of 2023.

Key Points: 
  • Lumenix, a leader in building technologies and artificial intelligence, is set to install its world-leading and clinically-validated Artificially Intelligent Monitoring System (AIMS) platform technology at the Ottawa Hospital Civic Campus in the fall of 2023.
  • "The partnership between Lumenix, The Ottawa Hospital and The Ottawa Hospital Research Institute exemplifies the potential of collaboration in driving meaningful advancements in patient care while identifying operating efficiencies to empower our clinical care workers."
  • This collaboration solidifies the commitment of Lumenix, TOH and OHRI to ethically usher in the future of artificial intelligence in healthcare.
  • For more information about Lumenix, please visit: www.lumenix.com or contact Lumenix at [email protected]
    For more information about AIMS, please visit: www.aimsplatform.i o or contact Lumenix at [email protected] .

Dr. Charmaine Lok and Dr. Allen R. Nissenson Join PatenSee's Scientific Advisory Board

Retrieved on: 
Wednesday, September 20, 2023
Ottawa Hospital Research Institute, David Geffen School of Medicine at UCLA, National Kidney Foundation, Rockwell Medical, Kidney failure, University, Emeritus, Stenosis, Teaching, Physician, Renal replacement therapy, Coronavirus Scientific Advisory Board, Research, Mentorship, Associate, University Health Network, Dialysis, ASN, Patient, NKF, Nursing, DaVita Inc., Kidney, Renal Physicians Association, Reading, BPS Barbara Wilson Lifetime Achievement Award, ISCB Senior Scientist Award, Vascular access, UCLA, Therapy, Conference, Chronic kidney disease, Kidney disease, Award, Fistula, Medical device, Pharmaceutical industry, Medicine

OR YEHUDA, Israel, Sept. 20, 2023 /PRNewswire/ -- Dr. Charmaine Lok is the new Chairperson of the PatenSee Scientific Advisory Board. The company also announced today that Dr. Allen R. Nissenson has joined the company as a strategic advisor. PatenSee is developing a contactless imaging system to provide rapid vascular access monitoring for hemodialysis patients.

Key Points: 
  • OR YEHUDA, Israel, Sept. 20, 2023 /PRNewswire/ -- Dr. Charmaine Lok is the new Chairperson of the PatenSee Scientific Advisory Board.
  • The company also announced today that Dr. Allen R. Nissenson has joined the company as a strategic advisor.
  • I am delighted to join PatenSee as the chairperson of its Scientific Advisory Board and look forward to guiding this technology's further development to rapidly make it available for improving patient outcomes," said Dr. Lok.
  • Dr. Nissenson currently serves on the Board of Directors of Elicio Therapeutics, Rockwell Medical, Innocura Nephrology and Diality Inc.

Ottawa OBGYN becomes new president of the SOGC

Retrieved on: 
Friday, June 9, 2023
University, Obstetrics, OHRI, Society of Obstetricians and Gynaecologists of Canada, Birth, The Ottawa Hospital, CHEO, Research, ACSC, Public health, Publication, Johns Hopkins University, Adolescence, Gynaecology, Ottawa Hospital Research Institute, Mortality, Professional degrees of public health, Conference, University of Ottawa Heart Institute, Birth control

OTTAWA, June 09, 2023 (GLOBE NEWSWIRE) -- Today, a physician from Ottawa, Dr. Amanda Black became the new president of the Society of Obstetricians and Gynaecologists of Canada (SOGC) at their Annual Clinical Scientific Conference (ACSC 2023).

Key Points: 
  • OTTAWA, June 09, 2023 (GLOBE NEWSWIRE) -- Today, a physician from Ottawa, Dr. Amanda Black became the new president of the Society of Obstetricians and Gynaecologists of Canada (SOGC) at their Annual Clinical Scientific Conference (ACSC 2023).
  • Dr. Black is a Professor of Obstetrics and Gynecology at The University of Ottawa.
  • She holds appointments at The Ottawa Hospital and CHEO and is an Associate Scientist at the Ottawa Hospital Research Institute (OHRI).
  • Dr. Black holds the Dr. Elaine Jolly Chair in Women’s Health Research at The University of Ottawa.

Find Therapeutics welcomes Dr. Jack Antel to its clinical advisory board

Retrieved on: 
Monday, May 1, 2023
Sclerosis, Optic neuritis, Multiple Sclerosis Journal, Cleveland Clinic, Specialist, University, CAB, National Multiple Sclerosis Society, Clinical trial, KNEEMO Initial Training Network, American Academy, Research, University of Ottawa Heart Institute, Department of Neurology, Xuanwu hospital, Multiple sclerosis, MS, Teaching hospital, Multiple Sclerosis Society, Neuro-ophthalmology, Patient, Montreal Neurological Institute and Hospital, University of Genoa, McGill University Health Centre, Soft tissue injury, McGill University, ISCB Senior Scientist Award, Ottawa Hospital Research Institute, Neurosurgery, American Academy of Neurology, Therapy, International Society, Pharmaceutical industry, Management, Medical device, Neurology, Biostatistics

MONTREAL, May 1, 2023 /PRNewswire/ - Find Therapeutics Inc., a biopharmaceutical company focused on the development of innovative therapies for autoimmune diseases, today announced the appointment of Dr. Jack Antel to its Clinical Advisory Board (CAB).

Key Points: 
  • MONTREAL, May 1, 2023 /PRNewswire/ - Find Therapeutics Inc., a biopharmaceutical company focused on the development of innovative therapies for autoimmune diseases, today announced the appointment of Dr. Jack Antel to its Clinical Advisory Board (CAB).
  • Dr. Antel joins a CAB with considerable expertise in neuro-ophthalmology whose members have decades of clinical practice with optic neuritis patients as well as clinical trial expertise and peer-reviewed publications in this condition.
  • Dr. Antel is an internationally acclaimed clinical neurologist and thought leader who coordinates the multiple sclerosis research and treatment program at the Montreal Neurological Institute.
  • "We are honored and delighted to welcome Dr. Antel to our Clinical Advisory Board.

Pan-Biome Pharmaceuticals, a startup focused on age-related diseases and increasing human healthspan, reports positive results in a preclinical trial of colitis

Retrieved on: 
Tuesday, April 25, 2023
Health Promotion International, Exercise, Spanish National Center for Biotechnology, TNF, Diabetes, CSO, Inflammaging, AMPK, NRF2, Colitis, Ageing, IL-6, Brain, Inflammation, Doctor of Philosophy, Oxidative stress, Metabolism, Ottawa Hospital Research Institute, Chronic condition, Mouse, Cytokine, Longevity, Notifiable disease, Rheumatoid arthritis, Conditional sentence, Pharmaceutical industry, Vaccine, NFE2L2

We have found that the compound demonstrates selective antimicrobial activity and has the ability to modulate the gut microbiome in mice.

Key Points: 
  • We have found that the compound demonstrates selective antimicrobial activity and has the ability to modulate the gut microbiome in mice.
  • Most age-related diseases are accompanied by chronic low-grade inflammation (Inflammaging), resulting in higher levels of pro-inflammatory cytokines in the bloodstream.
  • Pan-Biome’s lead compound activates anti-inflammatory cytokine IL-10 and inhibits the major pro-inflammatory cytokines TNF-a, IL-1b, and IL-6.
  • Pan-Biome CSO Dr. Poul Sorensen: “While we are still working out the mechanism, our compound most likely optimizes mitochondrial functionality.